scholarly journals TR3 enhances AR Variant Production and Transactivation, Increasing Androgen Independency of AR Signaling in Prostate Cancer Cells

Author(s):  
Tuyen Thanh Tran ◽  
Keesook Lee

Abstract Background Increased expression of constitutively active androgen receptor variants (AR-Vs) is associated with the development of advanced castration-resistant prostate cancer. The pro-oncogenic function of TR3, an orphan nuclear receptor, has been reported in various cancers including prostate cancer. However, the roles of TR3 in androgen receptor (AR) expression and signaling in prostate cancer cells are poorly understood. Methods Western blotting and quantitative RT-PCR were used to evaluate AR and AR-V expression levels affected by TR3 expression level. RNA-seq analysis, coimmunoprecipitation, cross-linked RNA-immunoprecipitation, and single-strand RNA protection and pull-down assays were conducted to elucidate the molecular mechanisms by which TR3 affected AR-V production. Results Database analysis revealed that TR3 expression level is elevated in prostate tumors, and is positively correlated with that of AR. TR3 overexpression increased the production of AR splice variants in addition to general upregulation of AR expression. TR3 interacted with some spliceosomal complex components and AR precursor mRNA, altering the splice junction rates between exons. TR3 also enhanced androgen-independent AR function. Furthermore, TR3 overexpression increased cell proliferation and mobility of AR-positive prostate cancer cells and stimulated tumorigenesis of androgen-independent prostate cancer cells in mouse xenograft models. This is the first study to report that TR3 is a multifunctional regulator of AR signaling in prostate cancer cells. Conclusions TR3 alters AR expression, splicing process, and activity in prostate cancer cells, increasing the androgen independency of AR signaling. Therefore, TR3 may play a crucial role in the progression of prostate cancer to advanced castration-resistant form.

2018 ◽  
Vol 61 (19) ◽  
pp. 8625-8638 ◽  
Author(s):  
Martina Tassinari ◽  
Graziella Cimino-Reale ◽  
Matteo Nadai ◽  
Filippo Doria ◽  
Elena Butovskaya ◽  
...  

2014 ◽  
Vol 53 (1) ◽  
pp. 31-41 ◽  
Author(s):  
Momoe Itsumi ◽  
Masaki Shiota ◽  
Akira Yokomizo ◽  
Ario Takeuchi ◽  
Eiji Kashiwagi ◽  
...  

Phorbol 12-myristate 13-acetate (PMA) induces cellular apoptosis in prostate cancer cells, the growth of which is governed by androgen/androgen receptor (AR) signaling, but the mechanism by which PMA exerts this effect remains unknown. Therefore, in this study, we investigated the mechanistic action of PMA in prostate cancer cells with regard to AR. We showed that PMA decreased E2F1 as well as AR expression in androgen-dependent prostate cancer LNCaP cells. Furthermore, PMA activated JNK and p53 signaling, resulting in the induction of cellular apoptosis. In LNCaP cells, androgen deprivation and a novel anti-androgen enzalutamide (MDV3100) augmented cellular apoptosis induced by PMA. Moreover, castration-resistant prostate cancer (CRPC) C4-2 cells were more sensitive to PMA compared with LNCaP cells and were sensitized to PMA by enzalutamide. Finally, the expression of PKC, E2F1, and AR was diminished in PMA-resistant cells, indicating that the gain of independence from PKC, E2F1, and AR functions leads to PMA resistance. In conclusion, PMA exerted its anti-cancer effects via the activation of pro-apoptotic JNK/p53 and inhibition of pro-proliferative E2F1/AR in prostate cancer cells including CRPC cells. The therapeutic effects of PMA were augmented by androgen deletion and enzalutamide in androgen-dependent prostate cancer cells, as well as by enzalutamide in castration-resistant cells. Taken together, PMA derivatives may be promising therapeutic agents for treating prostate cancer patients including CRPC patients.


Sign in / Sign up

Export Citation Format

Share Document